iStent Inject in OAG Subjects on 2 Pre-op Topical Ocular Hypotensive Medications

Glaukos Corporation6 enrolled

Overview

The purpose of this study is to evaluate the intraocular pressure (IOP) lowering effect of iStent inject in eyes of subjects with primary open-angle glaucoma previously on two anti-glaucoma medications.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Primary Open Angle Glaucoma (POAG)

Interventions

iStent inject surgeryDEVICE

Micro-invasive glaucoma surgery (MIGS) to implant iStent inject

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed with primary open angle glaucoma (POAG) * Subject on two ocular hypotensive medications Exclusion Criteria: * Traumatic, uveitic, neovascular, or angle closure glaucoma * Fellow eye already enrolled

Locations (1)

Department of Ophthalmology - UNIFESP/ Hospital São Paulo

São Paulo, Brazil

Outcomes

Primary Outcomes

IOP reduction at 12 and 24 months on same number or fewer medications

Time frame: 12 months and 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.